Teva's new migraine drug helps contain profit fall
Teva has reduced its spending by $2.5 billion since initiating the restructuring last year.
The CEO of Teva Pharmaceutical Industries Kare Schultz speaks during a news conference to discuss the company's 2019 outlooks in Tel Aviv, Israel February 19, 2019(photo credit: AMIR COHEN/REUTERS)
